Zevra Therapeutics Inc’s recent filing unveils that its Director Watton Corey Michael acquired Company’s shares for reported $3958.0 on Oct 11 ’24. In the deal valued at $7.92 per share,500 shares were bought. As a result of this transaction, Watton Corey Michael now holds 1,500 shares worth roughly $12075.000000000002.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Clifton R. LaDuane bought 2,000 shares, generating $13,540 in total proceeds. Upon buying the shares at $6.77, the CFO & Treasurer now owns 18,469 shares.
Before that, Anderson Thomas bought 10,000 shares. Zevra Therapeutics Inc shares valued at $68,065 were divested by the Director at a price of $6.81 per share. As a result of the transaction, Anderson Thomas now holds 20,000 shares, worth roughly $0.16 million.
Guggenheim initiated its Zevra Therapeutics Inc [ZVRA] rating to a Buy in a research note published on October 07, 2024; the price target was $20. A number of analysts have revised their coverage, including Maxim Group’s analysts, who remained covering the stock and in late September has reiterated a ‘”a Buy”‘ rating for it. JMP Securities began covering ZVRA with “Mkt outperform” recommendation on September 24, 2024. Maxim Group maintained its rating on April 02, 2024. It rated ZVRA as “a Buy”.
Price Performance Review of ZVRA
On Monday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock jump 3.87% to $8.05. Over the last five days, the stock has lost -5.74%. Zevra Therapeutics Inc shares have risen nearly 22.90% since the year began. Nevertheless, the stocks have risen 83.37% over the past one year. While a 52-week high of $8.95 was reached on 09/20/24, a 52-week low of $3.89 was recorded on 07/05/24. SMA at 50 days reached $7.66, while 200 days put it at $6.08.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 7.79, which if violated will result in even more drops to 7.53. On the upside, there is a resistance level at 8.23. A further resistance level may holdings at 8.41. The Relative Strength Index (RSI) on the 14-day chart is 52.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.32, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 62.75%. Stochastics %K at 29.14% indicates the stock is a holding.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2024-10-15, growing by 1.23 million shares to a total of 5.0 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 3.77 million shares. There was a rise of 24.67%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 12, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating .
